Skip to Content Julius Bär

Tracker Certificate on the China Healthcare Basket

  • The Chinese healthcare industry presents a truly remarkable growth story, driven by an ageing population, strong catch-up potential in healthcare spending relative to global standards and ample policy support.
  • Ongoing healthcare reforms in China are focused on cost control: they are expected to reduce waste and redundancy, focus on better medical drugs and devices, increase efficiency overall and enhance the quality of the care which the public receives.
  • Over the past few years, the Chinese government has stepped up its reforms in the medical drugs and devices market in particular, aiming to deliver cost savings to end-patients, as well as promote high product quality and foster domestic innovation.
  • Julius Baer Next Generation Research continues to primarily favour innovative, domestic medical drugs and device manufacturers with strong research and development capabilities as well as broad and diversified product pipelines.
  • We recommend participating in this theme by investing in a tracker certificate that provides access to the long-term secular trend of rising affluence and ageing in China, which is driving drug, hospital and healthcare technology markets.
  • The Julius Baer Tracker Certificate on the China Healthcare Basket 2018-B consists of 11 shares and allows the investor to fully participate in the performance of the underlyings. 
Back to top